Indications and Purposes
| 1 Indications And Usage Actemra ® (Tocilizumab) Is An Interleukin-6 (Il-6) Receptor Antagonist Indicated For Treatment Of: Rheumatoid Arthritis (Ra) ( 1.1 ) Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To One Or More Disease-Modifying Anti-Rheumatic Drugs (Dmards). Giant Cell Arteritis (Gca) ( 1.2 ) Adult Patients With Giant Cell Arteritis. Polyarticular Juvenile Idiopathic Arthritis (Pjia) ( 1.3 ) Patients 2 Years Of Age And Older With Active Polyarticular Juvenile Idiopathic Arthritis. Systemic Juvenile Idiopathic Arthritis (Sjia) ( 1.4 ) Patients 2 Years Of Age And Older With Active Systemic Juvenile Idiopathic Arthritis. Cytokine Release Syndrome (Crs) ( 1.5 ) Adults And Pediatric Patients 2 Years Of Age And Older With Chimeric Antigen Receptor (Car) T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome. 1.1 Rheumatoid Arthritis (Ra) Actemra ® (Tocilizumab) Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To One Or More Disease-Modifying Anti-Rheumatic Drugs (Dmards). 1.2 Giant Cell Arteritis (Gca) Actemra ® (Tocilizumab) Is Indicated For The Treatment Of Giant Cell Arteritis (Gca) In Adult Patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (Pjia) Actemra ® (Tocilizumab) Is Indicated For The Treatment Of Active Polyarticular Juvenile Idiopathic Arthritis In Patients 2 Years Of Age And Older. 1.4 Systemic Juvenile Idiopathic Arthritis (Sjia) Actemra ® (Tocilizumab) Is Indicated For The Treatment Of Active Systemic Juvenile Idiopathic Arthritis In Patients 2 Years Of Age And Older. 1.5 Cytokine Release Syndrome (Crs) Actemra ® (Tocilizumab) Is Indicated For The Treatment Of Chimeric Antigen Receptor (Car) T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome In Adults And Pediatric Patients 2 Years Of Age And Older. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Tocilizumab |